Jazz and Concert Collaborate to Develop Deuterium-Modified Version of Xyrem®
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 3 (Table of Contents)
Published: 9 Mar-2013
DOI: 10.3833/pdr.v2013.i3.1908 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Jazz Pharmaceuticals has licensed exclusive worldwide rights to develop and commercialise Concert Pharmaceuticals’ deuterium-modified analogues of sodium oxybate (D-SXB), including its lead compound C-10323...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS